Department of Urology, Ioannina University School of Medicine, Ioannina, Greece.
1st Department of Urology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece.
Curr Pharm Des. 2021;27(23):2697-2713. doi: 10.2174/1381612826666200226121510.
The therapeutic range of cyclic nucleotide phosphodiesterase 5 inhibitors (PDE5) inhibitors is getting wider in the last years. This review study focuses on the potential employment of PDE5 inhibitors as an adjunct tool for the therapeutic management of male infertility. The literature tends to suggest a beneficial effect of PDE5 inhibitors on Leydig and Sertoli cells secretory function. It also appears that PDE5 inhibitors play a role in the regulation of the contractility of the testicular tunica albuginea and the epididymis. Moreover, scientific data suggest that PDE5 inhibitors enhance the prostatic secretory function leading to an improvement in sperm motility. Other studies additionally demonstrate the role of PDE5 inhibitors in the regulation of the sperm capacitation process. Placebo-controlled, randomized, blind studies are necessary to unambiguously incorporate PDE5 inhibitors as an adjunct tool for the pharmaceutical treatment of semen disorders and male infertility.
近年来，环核苷酸磷酸二酯酶 5 抑制剂（PDE5）的治疗范围越来越广。本综述研究重点关注 PDE5 抑制剂作为男性不育症治疗管理的辅助工具的潜在应用。文献倾向于表明 PDE5 抑制剂对 Leydig 和支持细胞分泌功能具有有益作用。此外，PDE5 抑制剂似乎在调节睾丸白膜和附睾的收缩功能方面发挥作用。此外，科学数据表明 PDE5 抑制剂可增强前列腺分泌功能，从而提高精子活力。其他研究还证明了 PDE5 抑制剂在调节精子获能过程中的作用。需要进行安慰剂对照、随机、双盲研究，以明确将 PDE5 抑制剂作为治疗精液异常和男性不育症的辅助药物。
